EventsThe 3rd International Online Conference on Biomimetics
Published
This submission belongs to the session S2. Biomimetic Materials—Structures, Surfaces and Interfaces of the event The 3rd International Online Conference on Biomimetics
Published date
19 Nov, 2026
Academic Editor
author-avatarXu Hou
Contribution&Funding
Funding: This work was supported by the Russian Science Foundation research grant No. 25-75-00151, https://rscf.ru/project/25-75-00151/
Citation
Daria Prilutskaya, Mariia Mollaeva, Sofia Kleimenova, Nikita G Yabbarov, Margarita Chirkina, Maria Sokol, Maksim A. Klimenko, Ivan Gulyaev, Maxim Vershinin, Elena Dmitrievna Nikolskaya, Olga Kamaeva, Preparation of biomimetic doxorubicin delivery systems based on extracellular vesicles and cell membranes, in Proceedings of The 3rd International Online Conference on Biomimetics, 24 November–26 November 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Preparation of biomimetic doxorubicin delivery systems based on extracellular vesicles and cell membranes

Sofia Kleimenova 1,2
image
Maxim Vershinin 1
image
Olga Kamaeva 3,4
1. Laboratory of Quantitative Oncology, Institute of Biochemical Physics NM Emanuel, Moscow, 119991, Russia
2. Institute of Biomedical Engineering, University of Science and Technology MISIS, Moscow, 119049, Russia
3. Laboratory of Quantitative Oncology, Institute of Biochemical Physics N.M. Emanuel, Moscow, 119334 , Russia
4. Institute of Biomedical Engineering, University of Science and Technology MISIS, Moscow, 119049, Russia
Abstract

Introduction. Cancer remains one of the most significant challenges in modern medicine. Chemotherapy is one of the major approaches to treating malignant tumors. However, its low selectivity is associated with various treatment-related adverse effects. Nanoscale drug delivery systems may reduce systemic toxicity by improving the delivery of therapeutic agents. One promising approach is the use of hybrid extracellular vesicles (EVs) and cell membranes (CMs) particles (HEVCMs), which are biomimetic delivery systems combining extracellular vesicles (EVs) and cell membranes (CMs). HEVCMs have the ability to bind to and be internalized by target cells due to the presence of extracellular vesicles. Additionally, the incorporation of cell membranes may help reduce the uptake of HEVCMs by the reticuloendothelial system, as they contain plasma membrane proteins that may prevent the system from recognizing them.

Materials and methods. EVs and cell membranes CMs were isolated from human embryonic kidney (HEK293) cells. EVs were isolated by ultrafiltration. CMs were obtained by sonication followed by purification using size-exclusion chromatography. HEVCMs were prepared by extrusion through polycarbonate membranes with a pore size of 100 nm using an Avanti Mini-Extruder. Doxorubicin (DOX) was used as a model drug. Several methods were tested for loading DOX into HEVCMs, including pH-gradient loading, ammonium sulfate gradient loading, co-incubation, and short-term sonication-assisted loading. Unincorporated DOX was removed using size-exclusion chromatography with a Sephadex G-25 column. The resulting HEVCMs were characterized by dynamic light scattering to determine their mean hydrodynamic diameter and polydispersity index. DOX content was determined spectrophotometrically.

Results. Sonication-assisted loading resulted in HEVCMs with an average hydrodynamic diameter of about 101 ± 22 nm and a relatively monodisperse particle population (PDI=0.209). This method also provided the highest DOX incorporation efficiency (~6%). In contrast, the other loading methods produced polydisperse HEVCMs fractions with considerably larger particle sizes and lower DOX incorporation. The pH-gradient method resulted in a mean particle size of 247 ± 187 nm (PDI=0.462) and a DOX incorporation efficiency of <1%; the ammonium sulfate gradient method yielded particles with a mean size of 777 ± 359 nm (PDI=0.534) and a DOX incorporation efficiency of <1%; and co-incubation resulted in particles with a mean size of 389 ± 182 nm (PDI=0.650) and a DOX incorporation efficiency of ~1%.

Conclusions. Sonication was selected as the preferred method for loading DOX into HEVCMs because it provided sufficient drug incorporation efficiency, maintained monodispersity of the sample, and did not lead to aggregate formation. Thus, the developed HEVCMs-based system represents a promising platform for drug delivery and require further in vitro testing to evaluate their effectiveness and safety.

This work was supported by the Russian Science Foundation research grant No. 25-75-00151, https://rscf.ru/project/25-75-00151/

Keywords
Extracellular vesicles; Cell membrane; Hybrid nanoparticles; Cancer drug delivery; Doxorubicin
Photocurable carbon-containing hydrogels for neural interfaces: laser-induced formation and characterization
A Multi-Criteria Framework for Selecting Biomimetic Movement Mechanisms in Adaptive Façades